Predictors of Unfavourable Outcomes in Children and Adolescents Submitted to Surgical Mitral Valvuloplasty Secondary to Chronic Rheumatic Heart Disease

Renata Cristina Castro Cruz,1,2 Bruna Silva Cordeiro,2,3 Felipe de Souza Santos,2,3 Caroline Rodrigues Fernandes,4
Julia Maria Alves Gama,1 Ana Marice Teixeira Ladeia1

Escola Bahiana de Medicina e Saúde Pública,1 Salvador, BA – Brazil
Faculdade de Tecnologia e ciências,2 Salvador, BA – Brazil
Universidade Federal da Bahia,3 Salvador, BA – Brazil

Abstract

Background: Mitral valve repair in paediatric patients with chronic rheumatic heart disease is superior to valve replacement and has been used with good results.

Objective: To identify predictors of unfavourable outcomes in children and adolescents submitted to surgical mitral valvuloplasty secondary to rheumatic heart disease.

Methods: Retrospective study of 54 patients under the age of 16 operated at a tertiary paediatric hospital between March 2011 and January 2017. The predictors of risk for unfavourable outcomes were: age, ejection fraction, degree of mitral insufficiency, degree of pulmonary hypertension, presence of tricuspid insufficiency, left chamber dilation, preoperative functional classification, duration of cardiopulmonary bypass, duration of anoxia, presence of atrial fibrillation, and duration of vasoactive drug use. The outcomes evaluated were: death, congestive heart failure, reoperation, residual mitral regurgitation, residual mitral stenosis, stroke, bleeding and valve replacement. For all analyzes a value of p < 0.05 was established as significant.

Results: Of the patients evaluated, 29 (53.7%) were female, with an average of 10.5 ± 3.2 years. The functional classification of 13 patients (25%) was 4. There was no death in the sample studied. The average duration of extracorporeal circulation was 62.7±17.8 min, and anoxia 50 ± 15.7 min. The duration of use of vasoactive drug in the immediate postoperative period has an average of 1 day (interquartile interval 1–2 days). The logistic regression model was used to evaluate the predictive variables for each unfavourable outcome. The duration of use of vasoactive drug was the only independent predictor for the outcomes studied (p = 0.007). Residual mitral insufficiency was associated with reoperation (p = 0.044), whereas tricuspid insufficiency (p = 0.012) and pulmonary hypertension (p = 0.012) were associated with the presence of unfavourable outcomes.

Conclusion: The duration of vasoactive drug use is an independent predictor for unfavourable outcomes in the immediate and late postoperative period, while residual mitral regurgitation was associated with reoperation, and both tricuspid regurgitation and pulmonary hypertension were associated with unfavourable outcomes. (Arq Bras Cardiol. 2019; 113(4):748-756)

Keywords: Heart Defects, Congenital; Mitral Valve Insufficiency/surgery; Hypertension, Pulmonary; Reoperation; Tricuspid Valve Insufficiency/surgery; Cardiopathy, Rheumatic.

Introduction

Chronic rheumatic heart disease (RHD) consists of a non-suppurative complication of rheumatic fever (RF), with uni- or multivalvar involvement, which can lead to severe heart failure. It is estimated that each year there are 470,000 new cases of RF and 233,000 deaths attributed to RF or RHD. Mitral valve regurgitation is the main cause of RHD in children; when moderate or severe rheumatic valve disease is associated with pulmonary hypertension and left ventricular dysfunction, the development of congestive heart failure suggests the need for surgical intervention. Chronic rheumatic disease and its complications generated, in Brazil, 6,648 hospitalizations and a cost of BRL 73,067,919.52 in 2017 alone. Problems inherent to mitral valve replacement include the need for long-term anticoagulation, risk of bleeding, thromboembolism, endocarditis and lack of growth potential of the prosthesis, which makes the mitral valve plasty (MVP) technique superior to valve replacement in pediatric patients. However, patients submitted to valvuloplasty had a higher reoperation rate in the short term. This study aimed to identify predictors of unfavorable outcome in children and adolescents submitted to mitral valvuloplasty secondary to rheumatic heart disease.
Methods

A retrospective cohort study was performed. Data were collected by reviewing information on medical records (physical and electronic). The collection was performed by four researchers after standardized training. The Escola Bahiana de Medicina e Saúde Pública Research Ethics Committee approved this study together with CAAE from 64019316.0.000.5544.

Population

The study included 54 patients with mitral insufficiency of rheumatic etiology who underwent surgical correction by MVP technique, from March 2011 to January 2017.

Preoperative evaluation

Patients were clinically identified using the New York Heart Association (NYHA) Functional Classification.9 All medications that patients used continuously for at least one month were recorded. Valvular lesions were assessed by preoperative transthoracic echocardiography, classifying the lesions as “absent/discrete” or “moderate/significant”. Patients who presented another cause of valve damage at the time of surgical correction by MVP (infective endocarditis; congenital, post-traumatic, degenerative lesions or dystrophic lesions; cardiomyopathies or inflammatory or ischemic disease) or who underwent aortic valve surgery or other procedures in the same surgical time of MVP or an undocumented previous MVP were excluded, of which 7 had congenital mitral lesions (mitral dysplasia), 8 had undergone aortic valve replacement (other procedures), and 21 due to loss to follow-up or incomplete data.

Surgical technique

The reconstructive valve surgery technique was MVP, described by Carpentier,10 which includes annuloplasty and commissurotomy. The patients studied were preferably operated by the same medical team. The intraoperative data collected were: surgical technique used, duration of cardiopulmonary bypass (CPB), duration of anoxia and presence of atrial fibrillation. The intraoperative outcomes studied were: arrhythmia, cardiorespiratory arrest (CRA) and bleeding.

Follow-up

Follow-up was carried out within 60 days after surgery, in an outpatient setting, in a single centre. The predictors of risk for unfavourable outcomes studied were: age, ejection fraction, type of valve lesion, degree of mitral insufficiency (MI), left chamber dilatation, NYHA Preoperative Functional Classification, surgical technique used, duration of CPB, duration of anoxia, presence of atrial fibrillation, presence of pulmonary hypertension (PH) (sPAP > 35 mmHg) and presence of tricuspid insufficiency (TI).

Early (up to 7 postoperative days) and late (>7 days post-operative) outcomes related to heart valve disease were studied. The following were investigated: death, heart failure, cardiogenic shock, endocarditis, mitral valve damage, sepsis, stroke, bleeding, reoperation and valve replacement. The presence of any of these outcomes alone or in combination would characterize an unfavourable outcome as a single dependent variable.

Statistical analysis

The Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA), version 14.0 for Windows, was used for the elaboration of the database and for descriptive analysis. The results were presented in tables. Categorical variables were expressed in frequencies and percentages. Continuous variables with normal distribution were expressed as mean and standard deviation; those with non-normal distribution were expressed in median and interquartile range. The normality of the numerical variables was verified through descriptive statistics, graphical analysis and the Kolmogorov-Smirnov test.

The independent Student’s t test was used to compare groups of numerical variables with normal distribution (age, weight, body mass index – BMI, duration of anoxia, duration of CPB, ejection fraction). The Mann-Whitney test was used to compare numerical variables with asymmetric distribution, such as duration of use of vasoactive drugs (VAD).

The χ2 test was used to compare the use of medications in the preoperative and upon hospital discharge, and the intergroup comparison of the following categorical variables: gender, origin, outpatient follow-up, reoperations, functional classification, surgical team, events during surgery, duration of extubation and echocardiographic variables. When the distribution showed n < 5 individuals in each category, Fisher’s exact test was used.

The paired Student’s t-test was used for the numerical variable “ejection fraction” in the comparison of the paired groups (pre- and postoperative), and the McNemar test was used to compare the categorical variables of the echocardiogram. For all univariate analyses, a value of p < 0.05 was established.

The logistic regression model was used to evaluate the predictive variables for unfavourable outcomes in children and adolescents who underwent surgical mitral valvuloplasty secondary to rheumatic heart disease. After the univariate analysis, the independent variables were included in the logistic model if they presented p < 0.05, remaining in the model if they remained significant (p < 0.05). The manual procedure for insertion and withdrawal of the variables was adopted. Results were presented using Odds Ratio (OR) and their respective 95% confidence intervals (95% CI).

Results

From March 2011 to January 2017, 90 patients underwent surgery by the MVP technique in the tertiary hospital where the present study was carried out. Of these, 36 were excluded, of which 7 had congenital mitral lesions (mitral dysplasia), 8 had undergone aortic valve replacement associated with MVP and 21 due to loss to follow-up or incomplete data.

Characteristics of the sample studied

Table 1 shows clinical and demographic aspects of the 54 patients included, of which 29 (53.7%) were female, with a mean age of 10.5 ± 3.2 years. Of these patients, 34 (64.2%) lived on the countryside of the State of Bahia, 5 (9.4%) were from the Metropolitan Region and 14 (26.4%) were from the capital, Salvador. The mean BMI was 15.7 ± 3.5 kg/m2.
Prior to the surgery, 27 (51.9%) had regular outpatient follow-up. The disease duration until the surgery was a median of 8 months (interquartile range 5-36). The functional classification of 44 (81.48%) patients was between NYHA 2 and 4, with 13 (25%) being NYHA 4. None presented atrial fibrillation or had to undergo emergency surgery. There were no deaths in the sample studied.

Only 3 (5.6%) patients had to undergo reoperation, all of them undergoing a single reoperation. The causes were moderate to severe aortic regurgitation, leading to valve replacement in one patient on the 23rd postoperative day, and the other on the 45th. The third patient maintained severe MI even after correction, evolving with associated severe aortic insufficiency, undergoing reoperation for aortic and mitral valve replacement on the 45th day after repair.

Preoperative medications were grouped into 4 combinations: combination 1 – captopril and furosemide; combination 2 – captopril, furosemide and spironolactone; combination 3 – captopril, furosemide, spironolactone and digoxin; combination 4 – captopril, furosemide, spironolactone and carvedilol. Of these combinations, approximately half of the patients (55.8%) used combination 1. All patients had regular use of benzathine penicillin.

Table 1 – Characterization of sociodemographic and clinical variables of 54 children and adolescents with rheumatic mitral insufficiency undergoing mitral valvuloplasty

| Variables                        | Mean ± SD                        |
|----------------------------------|----------------------------------|
| **Age (years)**                  | 10.5 ± 3.2                       |
| **Weight (kg)**                  | 32.9 ± 14.3                      |
| **Height (m)**                   | 1.4 ± 0.2                        |
| **Body mass index (BMI) (kg/m²)**| 15.7 ± 3.5                       |
| **Time from disease to surgery (months)** | 8.00 (5.00–36.00)               |
| **Sex**                          | n (%)                            |
| Female                           | 29 (53.7)                        |
| Male                             | 25 (46.3)                        |
| **Origin**                       |                                  |
| Countryside                      | 34 (64.2)                        |
| Salvador                         | 14 (26.4)                        |
| Metropolitan Region              | 05 (9.4)                         |
| **Outpatient follow-up**         |                                  |
| Regular                          | 27 (51.9)                        |
| Irregular                        | 25 (48.1)                        |
| **Cardiac insufficiency**        |                                  |
| NYHA 1                           | 10 (18.5)                        |
| NYHA 2                           | 22 (40.7)                        |
| NYHA 3                           | 9 (16.7)                         |
| NYHA 4                           | 13 (24.1)                        |

SD: standard deviation; NYHA: New York Heart Association.

Intraoperative data

The patients underwent surgery with a standard surgical team in most cases, with only 2 procedures (3.8%) being performed by another team. The most used surgical technique was annuloplasty (96.2%), followed by commissurotomy 02 (3.8%), considering only the main procedure. There were events during surgery in 24 (44.4%) of the cases, including: severe bleeding (2), CRA (6), use of VAD (8) or others (8). The mean duration of CPB was 62.7 ± 17.8 min and anoxia was 50 ± 15.7 min. Extubation occurred within 6 hours postoperatively in 48 (92.3%) patients. The duration of VAD use in the immediate postoperative period had a median of 1 day (interquartile interval 1–2 days).

Description of preoperative and postoperative echocardiograms

Table 2 describes the data found in the preoperative and immediate postoperative echocardiogram (up to 7 postoperative days), comparing their results. The postoperative ejection fraction was reduced when compared to the preoperative one, 54.8 ± 13.9% and 70.2 ± 8.5%, respectively, with a value of p < 0.05. As for left chamber dilatation, 98% of the patients presented it preoperatively and 87% postoperatively. This reduction showed p = 0.063, demonstrating a trend towards significance.

Among the valve changes described in Table 2, moderate or significant aortic insufficiency was present in 13 (26.5%) patients in the preoperative period. In the postoperative period, only 8 (21.1%) had aortic insufficiency, but with no statistical significance (p = 1,000).

Moderate or significant MI was present in 48 (98%) patients in the preoperative period. Of these, none of the patients’ MI had worsened and 6 (15.8%) patients maintained moderate or significant postoperative MI (p < 0.001).

PH was present in 38 (77.6%) patients in the preoperative period and only 7 (18.4%) in the postoperative period. No patient progressed to PH or worsened in the postoperative period. On the other hand, 31 (81.6%) participants who had preoperative PH did not present it in the postoperative period (p < 0.001).

Analysis and description of outcomes

The presence of outcomes in the sample was divided into outcomes in the immediate postoperative period (up to 7 days) and in the late postoperative period (up to 60 days), as shown in Table 3. Seventeen patients presented an immediate postoperative outcome, mitral lesion (stenosis and/or residual insufficiency), being present in 8 (14.8%) patients. In the late postoperative period, 16 had outcomes, and mitral regurgitation was again the most common, presented by 11 (20.4%) patients.

The comparison between the use of medications in the preoperative period and after discharge and the outcomes did not present statistical significance, regardless of the combination used.

The variables that were related to the presence of late postoperative outcome were duration of CPB and duration of...
Table 2 – Description of surgical and echocardiographic variables in the preoperative and immediate postoperative periods of 54 children and adolescents with rheumatic mitral insufficiency undergoing mitral valvuloplasty

| Variables                              | Preoperative Mean ± SD | Post-operative Mean ± SD | p value |
|----------------------------------------|------------------------|--------------------------|---------|
| Duration of ECC (min)                  | 62.7 ± 17.8            | ---                      | ---     |
| Duration of anoxia (min)               | 50.0 ± 15.7            | ---                      | ---     |
| Duration of VAD use (days)             | ---                    | 1.0 (1.0 - 2.0)          | ---     |
| Ejection fraction (%)                  | 70.2 ± 8.5             | 54.8 ± 13.9              | 0.015†  |
| Dilation of left chambers              |                         |                          |         |
| No                                     | 01 (2.0)               | 06 (11.1)                | 0.063§  |
| Yes                                    | 48 (98.0)              | 32 (84.2)                |         |
| Mitral stenosis                        |                         |                          |         |
| Absent/discrete                        | 46 (93.9)              | 36 (94.7)                |         |
| Moderate/significant                   | 03 (6.1)               | 02 (5.3)                 | 1.000¥  |
| Aortic insufficiency                   |                         |                          |         |
| Absent/discrete                        | 36 (73.5)              | 30 (78.9)                |         |
| Moderate/significant                   | 13 (26.5)              | 08 (21.1)                | 1.000¥  |
| Aortic stenosis                        |                         |                          |         |
| Absent/discrete                        | 49 (100.0)             | 38 (100.0)               | ---     |
| Mitral insufficiency                   |                         |                          |         |
| Absent/discrete                        | 01 (2.0)               | 32 (84.2)                | 0.000§  |
| Moderate/significant                   | 48 (98.0)              | 06 (15.8)                |         |
| Tricuspid insufficiency                |                         |                          |         |
| Absent/discrete                        | 36 (73.5)              | 31 (81.6)                | 0.508§  |
| Moderate/significant                   | 13 (26.5)              | 07 (18.4)                |         |
| Pulmonary hypertension                 |                         |                          |         |
| No                                     | 11 (22.4)              | 31 (81.6)                | 0.000§  |
| Yes                                    | 38 (77.6)              | 07 (18.4)                |         |

ECC: extracorporeal circulation; VAD: vasoactive drug; † paired Student’s t test; ¥ McNemar test.

Discussion

MVP is universally accepted as superior to valve replacement (bioprostheses or metal prostheses), especially in children in whom growth, problems with anticoagulation, thromboembolism, rapid valve degeneration, increased risk of endocarditis and less preservation of ventricular function are unfavourable factors to this technique.6-8,10-12 In the tertiary hospital in which the study was performed, MVP is the preferred technique.

Patients in the study were followed up for two months after MVP, and in that period, there were no deaths in the sample studied. This is in accordance with the literature, in which the precocious or hospital mortality rate ranged from 0.9 to 3.5%.7,12,13

The literature lacks in studies that identify probable clinical predictors of negative outcomes in patients undergoing MVP surgery. In the present study, PH presented statistical significance for both immediate (≤7 days) and late (up to 60 days) postoperative outcomes in the univariate analysis.
Surgical mitral valvuloplasty in paediatric patients

Original Article

but did not maintain significance in the multivariate analysis. In their study of 122 mitral repairs, Kim et al.,14 after univariate and multivariate analysis, found preoperative pulmonary hypertension as the only independent risk factor for death (HR: 3.75 95%CI: 1.21–11.57; p = 0.022), but this study was carried out with adults with a mean age of 48.9 ± 11.5 years. The results in this study may differ from those found in the literature due to the sample size, as well as the age: the younger the sample, the higher the mortality rate and the higher the early rate of valve failure.15,17

In addition, postoperative TI was also a predictor of univariate analysis in this study, both in the immediate postoperative period and in the late postoperative period, but it lost significance in the multivariate analysis. No associations were found in the literature reviewed, but, like PH, TI is a criterion that should be valued. Although they were not independent predictors of outcomes, both variables were associated with unfavourable outcomes, both in the immediate and late postoperative period, with statistical significance, and should be used as initial points for surgical indication and follow-up in these patients.

Yakub et al.13 described residual mitral regurgitation ≥2 crosses as a predictor of valve failure and reoperation. In our study, the presence of moderate or significant residual MI in the postoperative period was associated with outcome both in the immediate and late postoperative period, in the univariate analysis, with statistical significance. Of the three children who underwent valve replacement, one presented moderate to severe mitral regurgitation even after attempted repair by MVP technique and the other two developed moderate to severe aortic regurgitation and underwent aortic valve replacement before completing sixty postoperative days. This data is in agreement with the literature in other studies as well, such as in those by Silva et al.11 and Severino et al.,15 always being a marker for reoperation. It is known that the late MVP results also depend on good coaptation of the cusps, which can be obtained through association of surgical techniques and reassessed at the end of the repair, whenever possible with intraoperative transesophageal echocardiography,19 which is not available in the hospital in which the study was carried out.

The mean duration of ECC found was 62.7 ± 18.8 minutes and the duration of anoxia was 50.0 ± 15.7 minutes, showing an association with the outcomes in the immediate postoperative period. In fact, in the literature, duration of CPB has been described as an independent predictor for cardiac surgeries, usually due to inflammatory factors in the bloodstream. Thus, it is well established that a CPB time longer than 90 minutes is associated with a more complicated postoperative period. The study by Talwar et al.16 showed duration of CPB of 47.6 ± 11.9 and duration of anoxia of 37.2 ± 12.8, and when assessed for association with early death or reoperation, no significance was found.16 This divergence with the literature may be due to the longer duration of both CPB and anoxia found in our sample.

The ECC time found in this study may have been influenced by variables that were not studied, such as anatomical differences, anterior leaflet involvement, thickening of the ribs, calcifications and papillary muscle involvement. Non-standardization of intraoperative and echocardiographic records, as well as the retrospective nature of the study, prevented the analysis of these data.

The duration of VAD use in the immediate postoperative period was found as a predictor for outcome in this study. Silva et al.11 also described the use of VAD, finding OR of 1.47 (95% CI 0.32-6.83), but they did not present statistical association in their sample. Other variables may have influenced this divergence in results, such as longer duration of CPB and anoxia in the study by Silva et al.11

The use of drugs for clinical optimization of CHF, due to the volume overload generated by mitral annular dilatation, also did not present significance and no description of the study of this variable was found in the reviewed literature, except in the study by Silva et al.,11 in which there is only a description of the use of anticongestive medications in 40% of patients in the preoperative period, not presenting a statistical analysis of this data.

The variables age, weight, height, duration of illness until surgery, NYHA preoperative classification, presence of atrial fibrillation and use of drugs were not significant in this study. In the studies by Talwar et al.16 and Kalfa et al.,17 these data were evaluated descriptively without statistical analysis and using only residual MI, reoperation, valve replacement and mortality as the outcome, without considering other variables such as bleeding, CHF and sepsis as possible outcomes.

---

Table 3 – Description of the immediate and late outcomes (and combined outcomes) of 54 children and adolescents with rheumatic mitral disease undergoing mitral valvuloplasty

| Variables                                      | n (%)   |
|-----------------------------------------------|---------|
| Immediate outcome (n = 54)                    |         |
| None                                          | 37 (68.6)|
| CHF                                           | 01 (1.9) |
| Sepsis                                        | 01 (1.9) |
| Mitral lesion*                                | 04 (7.4) |
| Others                                        | 04 (7.4) |
| Bleeding and others                           | 02 (3.7) |
| CHF and mitral lesion *                       | 01 (1.9) |
| Others and CHF                                | 01 (1.9) |
| Mitral lesion* and others                     | 02 (3.7) |
| Mitral lesion* and bleeding                    | 01 (1.9) |
| Late outcome (n = 54)                         |         |
| None                                          | 38 (70.4)|
| CHF                                           | 01 (1.9) |
| Reoperation/valve replacement (up to 30 days) | 03 (5.6) |
| Mitral lesion*                                | 11 (20.4)|
| Others                                        | 01 (1.9) |

*mitral lesion: mitral stenosis and/or residual mitral insufficiency; n: number of participants; CHF: congestive heart failure.
### Table 4 – Comparison between clinical and echocardiographic variables in the postoperative period with clinical outcomes in 54 children and adolescents with rheumatic mitral insufficiency undergoing mitral valvuloplasty

| Variables                      | Imediate postoperative period (up to 7 days) | Late postoperative period (up to 60 days) | p value |
|--------------------------------|---------------------------------------------|-------------------------------------------|---------|
|                                | Yes mean ± SD                               | No mean ± SD                               |         |
| Duration of VAD use (days)     | 3.0 (1.0–3.0)                               | 1.0 (1.0–2.0)                              | 0.009†  |
|                                |                                             |                                           |         |
| Ejection fraction (%)          | 54.7 ± 17.6                                 | 54.9 ± 10.6                                | 0.962*  |
|                                |                                             |                                           |         |
| Dilatation of left chambers    | n (%)                                       | n (%)                                      | 0.846‡  |
|                                |                                             |                                           |         |
| No                             | 02 (14.3)                                   | 04 (16.7)                                 | 02 (16.7)| 04 (15.4)| 0.920‡  |
| Yes                            | 12 (85.7)                                   | 20 (83.3)                                 | 10 (83.3)| 22 (84.6)|         |
| Mitral stenosis                |                                             |                                           |         |
| Absent/discrete                | 12 (85.7)                                   | 24 (100.0)                                | 0.057*  |
| Moderate/significant           | 02 (14.3)                                   | 00 (00.0)                                 | 02 (16.7)| 00 (00.0)| 0.094*  |
| Aortic insufficiency           |                                             |                                           |         |
| Absent/discrete                | 10 (71.4)                                   | 20 (83.3)                                 | 0.385‡  |
| Moderate/significant           | 04 (28.6)                                   | 04 (16.7)                                 | 03 (25.0)| 05 (19.2)| 0.685‡  |
| Aortic stenosis                |                                             |                                           |         |
| Absent/discrete                | 14 (100.0)                                  | 24 (100.0)                                |         |         |
| Mitral insufficiency           |                                             |                                           |         |
| Absent/discrete                | 09 (64.3)                                   | 23 (95.8)                                 | 0.010‡  |
| Moderate/significant           | 05 (35.7)                                   | 01 (4.2)                                  | 04 (33.3)| 02 (7.7 )| 0.044‡  |
| Tricuspid insufficiency        |                                             |                                           |         |
| Absent/discrete                | 09 (64.3)                                   | 22 (91.7)                                 | 0.036‡  |
| Moderate/significant           | 05 (35.7)                                   | 02 (8.3)                                  | 05 (41.7)| 02 (7.7 )| 0.012‡  |
| Pulmonary hypertension         |                                             |                                           |         |
| No                             | 09 (64.3)                                   | 22 (91.7)                                 | 0.036‡  |
| Yes                            | 05 (35.7)                                   | 02 (8.3)                                  | 05 (41.7)| 02 (7.7 )| 0.012‡  |

n: number of participants; SD: standard deviation; IQ: interquartile range; VAD: vasoactive drugs; *independent Student’s t test; †Mann-Whitney’s test; ¥χ² test or Fisher’s exact test.

### Table 5 – Predictive variables for immediate and late outcomes in 54 children and adolescents with rheumatic mitral insufficiency undergoing mitral valvuloplasty

| Variables                      | Input Model | Final Model | p value | p value |
|--------------------------------|-------------|-------------|---------|---------|
|                                | OR (95%CI)  | p value     | OR (95%CI) | p value |
| Immediate outcome              |             |             |         |         |
| Sex                            | 3.6 (0.8–15.0) | 0.084 | - | - |
| Duration of VAD use (days)     | 2.4 (1.2–4.9) | 0.014 | 2.5 (1.3–4.9) | 0.007 |
| Late outcome                   |             |             |         |         |
| Days of VAD                    | 1.8 (0.9–3.7) | 0.95 | - | - |
| Number of reoperations         | 1.8 (0.1–31.7) | 0.683 | - | - |
| Duration of ECC (min)          | 1.0 (0.9–1.1) | 0.538 | 1.0 (1.0–1.1) | 0.051 |
| Duration of anoxia (min)       | 1.0 (0.9–1.1) | 0.958 | - | - |
| Extubation (hour)              | 5.2 (0.4–67.3) | 0.211 | - | - |

OR: Odds Ratio; 95%CI: 95% confidence interval; logistic regression.
The literature presents other outcome predictors that were not identified or not studied in our sample, such as ventricular dysfunction, studied by Talwar et al.,\textsuperscript{16} with HR 4.9 (95%CI 2.65–9.2), \( p < 0.005 \). On the other hand, Yakub et al.\textsuperscript{13} described the NYHA preoperative classification, emergency surgeries and double valvular lesions as predictors of early death.

In our country, rheumatic disease is the main cause of acquired heart diseases in childhood and adolescence, unlike in developed countries, where Kawasaki disease is the most frequent cause of acquired heart disease in the paediatric age group.\textsuperscript{19,20} In this context, degenerative lesions are the main indications of mitral valve repair, which justifies the small number of studies found, taking into account only valvular corrections by MVP technique for valve sequelae due to chronic RHD in the pediatric age group.\textsuperscript{21}

Although Brazil is considered a high risk country for RF, with 40% of heart surgeries being performed for valve repairs due to chronic RHD sequelae, according to data from the Department of Informatics of the Unified Health System (DATASUS),\textsuperscript{5} only a few Brazilian studies were found involving the theme addressed in the present study, and only one of them comprising the paediatric age group, all focusing on surgical results. Murad et al.\textsuperscript{7} studied 86 patients with a mean age of 35.8 years and concluded that MVP can be performed with low mortality and should be the procedure of choice in patients with MI. Similarly, Pomerantzef et al.\textsuperscript{22} studied 330 patients with a mean age of 26.9 ± 15.4 years for 20 years and concluded that the MVP technique is feasible in rheumatic patients with low early and late mortality. Severino et al.,\textsuperscript{15} in a study with 104 adult patients (mean age 32.73 ± 14.74 years) evaluating MVP results in rheumatic patients, found that late reoperation was associated with postoperative residual MI (\( p < 0.001 \)), presence of PH (\( p < 0.01 \)), age (\( p < 0.04 \)) and postoperative functional classification (\( p < 0.001 \)). Silva et al.\textsuperscript{11} evaluated the outcome of valve reconstruction in rheumatic lesions in 40 patients younger than 18 years after 4 years of evolution and did not find statistically significant risk factors that could interfere with the evolution of patients in relation to valve replacement before 4 years. The studied variables included: functional classification in the pre- and postoperative period, amount of drugs used by patients at the time of surgery, duration of CPB and anoxia and need for VAD in the immediate postoperative period.

To date, no study has been published in the North and Northeast Regions involving patients with chronic RHD, although the socioeconomic characteristics of these regions are strong factors for a higher prevalence of chronic RHD in the country. In the Brazilian articles published by Severino et al.\textsuperscript{15} and by Silva et al.\textsuperscript{11} there is no report of the origin of the patients operated by the MVP technique, nor were they intended to look for possible predictors for other unfavourable outcomes besides reoperation and mortality.

Because the surgical indications for mitral repair in the paediatric population do not have well-defined criteria in the literature, they require previous discussions and interaction between paediatric cardiologists, cardiologists and cardiac surgeons in order to delineate and minimize factors that may contribute to a postoperative period in the short, medium and long term with good results.

This is a pioneer study, due to the characteristics already described, in an exclusively paediatric population, in a high-risk region for chronic RHD, which should elicit new discussions regarding the topic addressed. Because pathology has the special characteristic of being one of the rare rheumatic diseases whose etiologic agent is known and, therefore, has a specific treatment and can be avoided with the adoption of low-cost preventive measures with high effectiveness. Being the primary prophylaxis performed with low-cost and easily accessible antibiotics, valve sequelae and, consequently, cardiac surgeries could be avoided, reducing cost to society and improving the quality of life for the affected population.

Conclusion

The time of VAD use was an independent predictor for outcomes studied postoperatively. Residual MI was associated with reoperation, while TI and PH were associated with unfavourable outcomes in the immediate and late postoperative period. The data in this study allow new investigations to improve the prognosis of children and adolescents with chronic RHC submitted to the MVP repair technique.

Study limitations

The limitations of our study are related to its retrospective nature, sample size, and due to it being carried out in a single centre.

Author contributions

Conception and design of the research and Analysis and interpretation of the data: Cruz RCC, Cordeiro BS, Santos FS, Fernandes CR, Gama JMA, Ladeia AMT; Acquisition of data, Statistical analysis and Writing of the manuscript: Cruz RCC, Cordeiro BS, Santos FS, Fernandes CR, Gama JMA; Critical revision of the manuscript for intellectual content: Cruz RCC, Ladeia AMT.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This article is part of the thesis of master submitted by Renata Cristina Castro Cruz, from Escola Bahiana de Medicina e Saúde Pública.

Ethics approval and consent to participate

The Escola Bahiana de Medicina e Saúde Pública Research Ethics Committee approved this study together with CAAE from 64019316.0.0000.5544.
References

1. World Health Organization. (WHO). Rheumatic fever and rheumatic heart disease. WHO [Internet]. 2013 [cited 2018 Mar 27]; Available from: http://www.who.int/cardiovascular_diseases/publications/trs923/en/

2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685–94.

3. Zühlke L, Watkins D, Engel ME. Incidence, prevalence and outcomes of rheumatic heart disease in South Africa: a systematic review protocol. BMJ Open. 2014;4(1):e004844.

4. Sani MU, Karaye KM, Ibrahim DA. Cardiac morbidity in subjects referred for echocardiographic assessment at a tertiary medical institution in the Nigerian savanna zone. Afr J Med Med Sci. 2007;36(2):141–7.

5. Brasil. Ministério da Saúde. Sistema de Informações Hospitalares do SUS (SIH/SUS).

6. Hillman ND, Tani LY, Veasy LG, Lambert LL, Di Russo GB, Duty DB, et al. Current Status of Surgery for Rheumatic Carditis in Children. Ann Thorac Surg. 2004;78(4):1403–8.

7. Murad H, Gomes EC, Pinheiro AA, Azevedo JA de, Sá MPL de, Noronha AP, et al. Surgical treatment of mitral valve insufficiency by valve repair. Rev Bras Cir Cardiovasc 2002; 17(4):299–306.

8. Remenyi B, Webb R, Gentles T, Russell P, Finucane K, Lee M, et al. Improved Long-Term Survival for Rheumatic Mitral Valve Repair Compared to Replacement in the Young. World J Pediatr Congenit Heart Surg. 2013;4(2):155–64.

9. New York Heart Association. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston; 1944. p. 253–6.

10. Carpentier A. Cardiac valve surgery- the ”French correction” J Thorac Cardiovasc Surg. 1983;86(3):323–37.

11. Silva AR, Herdy GVH, Vieira AA, Simões LC. Plastia mitral cirúrgica em crianças com febre reumática. Arq Bras Cardiol. 2009;92(6):433–8.

12. Cardoso B, Loureiro P, Comes J, Gordo A, Banazol N, Fragata J, et al. Mitral Valve Surgery for Rheumatic Lesions in Young Patients. World J Pediatr Congenit Heart Surg. 2016;7(3):321–8.

13. Yakub MA, Krishna Moorthy PS, Sivalingam S, Dillon J, Kong PK. Contemporary long-term outcomes of an aggressive approach to mitral valve repair in children: is it effective and durable for both congenital and acquired mitral valve lesions? Eur J Cardio-Thoracic Surg 2016;49(2):553–60.

14. Kim JB, Kim HJ, Moon DH, Jung SH, Choo SJ, Chung CH, et al. Long-term outcomes after surgery for rheumatic mitral valve disease: valve repair versus mechanical valve replacement. Eur J Cardio-Thoracic Surg. 2010;37(5):1039–46.

15. Severino ESB, Petrucci O, Vilainho KA de S, Lavagnoli CFR, Silveira Filho LM, Oliveira PPM, et al. Resultados tardios da plastia mitral em pacientes reumáticos. Rev Bras Cir Cardiovasc. 2011;26(4):539–64.

16. Talwar S, Rajesh MR, Subramanian A, Saxena A, Kumar AS. Mitral valve repair in children with rheumatic heart disease. J Thorac Cardiovasc Surg. 2005;129(4):875–9.

17. Kalfa D, Vergnat M, Ly M, Ston B, Lambert V, Barateau A, et al. A standardized repair-oriented strategy for mitral insufficiency in infants and children: Midterm functional outcomes and predictors of adverse events. J Thorac Cardiovasc Surg. 2014;148(4):1459–66.

18. Yakub MA, Dillon J, Krishna Moorthy PS, Pau KC, Nordin MN. Is rheumatic aetiology a predictor of poor outcome in the current era of mitral valve repair? Contemporary long-term results of mitral valve repair in rheumatic heart disease†. Eur J Cardio-Thoracic Surg. 2013;44(4):673–81.

19. Gordon JB, Kahn AM, Burns JC. When Children With Kawasaki Disease Grow Up. J Am Coll Cardiol. 2009;54(21):1911–20.

20. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr. 1991;119(2):279–82.

21. Peioto A, Linhares L, Scherr P, Xavier R, Stefanni S, Pacheco T, et al. Febre reumática: revisão sistemática. Rev Bras Clin Med. 2011;9(3):234–8.

22. Pomerantzeff PMA, Brandão CM de A, Leite Filho OA, Guedes MAV, Silva MF da, Grinberg M, et al. Plástica da valva mitral em pacientes com insuficiência mitral reumática: técnicas e resultados de 20 anos. Rev Bras Cir Cardiovasc. 2009;24(4):485–9.
